BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

460 related articles for article (PubMed ID: 19805677)

  • 1. Reporting of time-to-event end points and tracking of failures in randomized trials of radiotherapy with or without any concomitant anticancer agent for locally advanced head and neck cancer.
    Le Tourneau C; Michiels S; Gan HK; Siu LL
    J Clin Oncol; 2009 Dec; 27(35):5965-71. PubMed ID: 19805677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival end point reporting in randomized cancer clinical trials: a review of major journals.
    Mathoulin-Pelissier S; Gourgou-Bourgade S; Bonnetain F; Kramar A
    J Clin Oncol; 2008 Aug; 26(22):3721-6. PubMed ID: 18669458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemoradiation after surgery for high-risk head and neck cancer patients: how strong is the evidence?
    Bernier J; Cooper JS
    Oncologist; 2005 Mar; 10(3):215-24. PubMed ID: 15793225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Absence of planned neck dissection for the N2-N3 neck after chemoradiation for locally advanced squamous cell carcinoma of the head and neck.
    Lau H; Phan T; Mackinnon J; Matthews TW
    Arch Otolaryngol Head Neck Surg; 2008 Mar; 134(3):257-61. PubMed ID: 18347249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck.
    Colevas AD
    J Clin Oncol; 2006 Jun; 24(17):2644-52. PubMed ID: 16763278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patterns of failure in patients with locally advanced head and neck cancer treated postoperatively with irradiation or concomitant irradiation with Mitomycin C and Bleomycin.
    Zakotnik B; Budihna M; Smid L; Soba E; Strojan P; Fajdiga I; Zargi M; Oblak I; Lesnicar H
    Int J Radiat Oncol Biol Phys; 2007 Mar; 67(3):685-90. PubMed ID: 17197122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Postoperative concurrent chemoradiotherapy with mitomycin in advanced squamous cell carcinoma of the head and neck: results from three prospective randomized trials.
    Rewari AN; Haffty BG; Wilson LD; Son YH; Joe JK; Ross DA; Papac RJ; Sasaki CT; Fischer JJ
    Cancer J; 2006; 12(2):123-9. PubMed ID: 16630403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer.
    Haddad R; Sonis S; Posner M; Wirth L; Costello R; Braschayko P; Allen A; Mahadevan A; Flynn J; Burke E; Li Y; Tishler RB
    Cancer; 2009 Oct; 115(19):4514-23. PubMed ID: 19634161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patterns of failure and toxicity after intensity-modulated radiotherapy for head and neck cancer.
    Schoenfeld GO; Amdur RJ; Morris CG; Li JG; Hinerman RW; Mendenhall WM
    Int J Radiat Oncol Biol Phys; 2008 Jun; 71(2):377-85. PubMed ID: 18164838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of treatment outcomes by radiochemotherapy and postoperative radiotherapy in locally advanced squamous cell carcinomas of head and neck.
    Fortin A; Caouette R; Wang CS; Vigneault E
    Am J Clin Oncol; 2008 Aug; 31(4):379-83. PubMed ID: 18845998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of tumor board recommendations on treatment outcome for locally advanced head and neck cancer.
    Nguyen NP; Vos P; Lee H; Borok TL; Karlsson U; Martinez T; Welsh J; Cohen D; Hamilton R; Nguyen N; Nguyen LM; Vinh-Hung V
    Oncology; 2008; 75(3-4):186-91. PubMed ID: 18841033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concomitant boost radiotherapy compared with conventional radiotherapy in squamous cell carcinoma of the head and neck--a phase III trial from a single institution in India.
    Ghoshal S; Goda JS; Mallick I; Kehwar TS; Sharma SC
    Clin Oncol (R Coll Radiol); 2008 Apr; 20(3):212-20. PubMed ID: 18343310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Altered fractionation and/or adjuvant chemotherapy in definitive irradiation of squamous cell carcinoma of the head and neck.
    Mendenhall WM; Riggs CE; Amdur RJ; Hinerman RW; Villaret DB
    Laryngoscope; 2003 Mar; 113(3):546-51. PubMed ID: 12616212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mcl-1, vascular endothelial growth factor-R2, and 14-3-3sigma expression might predict primary response against radiotherapy and chemotherapy in patients with locally advanced squamous cell carcinomas of the head and neck.
    Erovic BM; Pelzmann M; Grasl MCh; Pammer J; Kornek G; Brannath W; Selzer E; Thurnher D
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8632-6. PubMed ID: 16361547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiochemotherapy in locally advanced squamous cell carcinomas of the head and neck.
    Matzinger O; Zouhair A; Mirimanoff RO; Ozsahin M
    Clin Oncol (R Coll Radiol); 2009 Sep; 21(7):525-31. PubMed ID: 19535232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pretreatment quality of life predicts for locoregional control in head and neck cancer patients: a radiation therapy oncology group analysis.
    Siddiqui F; Pajak TF; Watkins-Bruner D; Konski AA; Coyne JC; Gwede CK; Garden AS; Spencer SA; Jones C; Movsas B
    Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):353-60. PubMed ID: 17889449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of epoetin alfa on survival and cancer treatment-related anemia and fatigue in patients receiving radical radiotherapy with curative intent for head and neck cancer.
    Hoskin PJ; Robinson M; Slevin N; Morgan D; Harrington K; Gaffney C
    J Clin Oncol; 2009 Dec; 27(34):5751-6. PubMed ID: 19884550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Individual patients' data meta-analyses in head and neck cancer.
    Bourhis J; Le MaƮtre A; Baujat B; Audry H; Pignon JP; ; ;
    Curr Opin Oncol; 2007 May; 19(3):188-94. PubMed ID: 17414635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CHART revisited: a conservative approach for advanced head and neck cancer.
    Saunders M; Rojas AM; Dische S
    Clin Oncol (R Coll Radiol); 2008 Mar; 20(2):127-33. PubMed ID: 18065214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiation treatment interruptions greater than one week and low hemoglobin levels (12 g/dL) are predictors of local regional failure after definitive concurrent chemotherapy and intensity-modulated radiation therapy for squamous cell carcinoma of the head and neck.
    McCloskey SA; Jaggernauth W; Rigual NR; Hicks WL; Popat SR; Sullivan M; Mashtare TL; Khan MK; Loree TR; Singh AK
    Am J Clin Oncol; 2009 Dec; 32(6):587-91. PubMed ID: 19581794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.